E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Comparison of characteristics, treatment, and outcomes of patients enrolled versus not enrolled in a clinical trial: findings from TIMI 9 Registry and 9b trial
Maria Cecilia Bahit,Elliott M. Antman,Sabina A. Murphy,Carolyn H. McCabe,Christopher P. Cannon +4 more
Book ChapterDOI
Cardioversion and Defibrillation
TL;DR: The development of capacitors capable of delivering single-pulse discharges set the stage for the production of the cardioversion/defibrillation apparatus in use today.
Journal ArticleDOI
861-3 A phase I open-label dose escalation trial of a monoclonal antibody against tissue factor (sunol cH36) in stable coronary artery disease: Results of the PROXIMATE-TIMI 27 trial
David A. Morrow,Rafael F. Sequeira,Tim Henry,Lawrence Galitz,Howard A. Cooper,Benjamin M. Scirica,Graham C. Wong,Hing C. Wong,Carolyn H. McCabe,Elliott M. Antman +9 more
TL;DR: In this initial experience in humans, cH36 exhibited dose-related anticoagulant effects manifest with minor bleeding, and it is postulate that the platelet-mediated bleeding observed with this potent inhibitor of thrombin generation reflects important networking betweenThrombin & platelet pathways that may prove clinically relevant with this novel class of antICOagulants.
Journal ArticleDOI
A new endpoint to evaluate the sucess of reperfusion therapy following ST-elevation myocardial infarction
Robert P. Giugliano,Marc S. Sabatine,C. Michael Gibson,Matthew T. Roe,Robert A. Harrington,Ghislaine Pisapia,David A. Morrow,Elliott M. Antman,Eugene Braunwald +8 more
Journal ArticleDOI
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.
Riccardo M. Inciardi,Robert P. Giugliano,Jeong Gun Park,Francesco Nordio,Christian T. Ruff,Cathy Chen,Hans Lanz,Elliott M. Antman,Eugene Braunwald,Scott D. Solomon +9 more
TL;DR: In this paper , the authors compared the risks of heart failure (HF) events compared with stroke/systemic embolic events (SEE) or major bleeding (MB) in heart failure with reduced ejection fraction (HFrEF) vs heart failure having preserved ejection fractions (HFpEF) in a large atrial fibrillation (AF) population.